Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Presage Biosciences Adds Board Member

Executive Summary

The oncology company Presage Biosciences has appointed David Johnson to its board of directors. With 25 years’ experience Johnson joins Presage from the oncology focused company, Acerta Pharma, where he was CEO.  He has held roles with increasing responsibilities within clinical development, medical affairs, pipeline development, and commercial at companies including Calistoga (acquired by Gilead), Gloucester (acquired by Celgene), Favrille, Millennium, Immunex (acquired by Amgen), and Hoffman La Roche.

You may also be interested in...



Coronavirus Update: Pfizer, BioNTech Hit Ground Running On Vaccine EUA

US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.

Executives On The Move: New CEOs Named At Gossamer Bio, Liminal BioSciences

Board directors appointed at Athersys, Trillium Therapeutics and Viatris

Coronavirus Update: CureVac's EU Vaccine Deal, J&J's New Vaccine Study, BioNTech/Fosun Get China Go-Ahead

CureVac seals EU Deal for 405 million doses of CVnCoV, a second Phase III trial for J&J’s COVID-19 vaccine starts, and BioNTech, Fosun get OK for China vaccine trial.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel